Literature DB >> 19357015

[Prognosis factors of cholangiocarcinoma: contribution of recent molecular biology tools].

G Malouf1, C Dreyer, N Guedj, V Paradis, F Degos, J Belghiti, C Le Tourneau, S Faivre, E Raymond.   

Abstract

Cholangiocarcinoma represents the second most common primary hepatobiliary cancer. Although few patients are candidates for surgery, surgical resection represents the only potential curative option. The prognosis for patients remains poor, despite advances in the understanding of mechanisms involved in carcinogenesis. This review aims to assess clinicopathological factors and biological markers for the ability to predict prognosis. Clinicopathologic factors most often cited are tumor size, lymph node involvement, resecability and surgical margins involvement. Molecular biomarkers have been examined and a number of these, including mdm2, p27, matrix metalloproteinases and vitamin D receptor appear to have prognostic utility. The advent of 'omic'-based profiling offers the potential to assess many different biomarkers at the same time. This 'protein/gene signature' could open the way for developing valid and reproducible predictors of survival based on protein or gene profiles.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357015     DOI: 10.1684/bdc.2008.0780

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  1 in total

1.  RNA interference targeting slug increases cholangiocarcinoma cell sensitivity to cisplatin via upregulating PUMA.

Authors:  Kejun Zhang; Dong Chen; Xingang Wang; Shaoyan Zhang; Jigang Wang; Yuan Gao; Bomin Yan
Journal:  Int J Mol Sci       Date:  2011-01-14       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.